JP2013537905A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537905A5
JP2013537905A5 JP2013530121A JP2013530121A JP2013537905A5 JP 2013537905 A5 JP2013537905 A5 JP 2013537905A5 JP 2013530121 A JP2013530121 A JP 2013530121A JP 2013530121 A JP2013530121 A JP 2013530121A JP 2013537905 A5 JP2013537905 A5 JP 2013537905A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
interleukin
additional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537905A (ja
JP5619289B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/050138 external-priority patent/WO2012039717A1/en
Publication of JP2013537905A publication Critical patent/JP2013537905A/ja
Publication of JP2013537905A5 publication Critical patent/JP2013537905A5/ja
Application granted granted Critical
Publication of JP5619289B2 publication Critical patent/JP5619289B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530121A 2010-09-24 2010-09-24 C型肝炎ウイルス阻害剤 Expired - Fee Related JP5619289B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/050138 WO2012039717A1 (en) 2010-09-24 2010-09-24 Hepatitis c virus inhibitors

Publications (3)

Publication Number Publication Date
JP2013537905A JP2013537905A (ja) 2013-10-07
JP2013537905A5 true JP2013537905A5 (enExample) 2013-11-14
JP5619289B2 JP5619289B2 (ja) 2014-11-05

Family

ID=43037168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530121A Expired - Fee Related JP5619289B2 (ja) 2010-09-24 2010-09-24 C型肝炎ウイルス阻害剤

Country Status (8)

Country Link
EP (1) EP2619195A1 (enExample)
JP (1) JP5619289B2 (enExample)
CN (1) CN103249730A (enExample)
BR (1) BR112013008148A2 (enExample)
CA (1) CA2812699A1 (enExample)
EA (1) EA201370078A1 (enExample)
MX (1) MX2013002927A (enExample)
WO (1) WO2012039717A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
EP2454254A2 (en) 2009-07-16 2012-05-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2616461A4 (en) 2010-08-26 2014-03-26 Rfs Pharma Llc POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
IN2014MN01547A (enExample) 2012-02-10 2015-05-08 Lupin Ltd
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA3055680A1 (en) 2017-03-31 2018-10-04 Syngenta Participations Ag Fungicidal compositions
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
WO2024259085A2 (en) * 2023-06-14 2024-12-19 Alexion Pharmaceuticals, Inc. Methods for the synthesis of complement factor d inhibitors and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
US7420079B2 (en) 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102004036971B4 (de) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010034721A (ja) * 2008-07-28 2010-02-12 Fujitsu Ltd パケットキャプチャ装置,パケットキャプチャ方法およびパケットキャプチャプログラム
EP2774927A1 (en) * 2008-12-03 2014-09-10 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) * 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Similar Documents

Publication Publication Date Title
JP2013507439A5 (enExample)
JP2014504643A5 (enExample)
ME02321B (me) Antivirusna jedinjenja
JP2012512169A5 (enExample)
JP2011528713A5 (enExample)
JP2014515377A5 (enExample)
JP2013514359A5 (enExample)
JP2013518107A5 (enExample)
JP2012528161A5 (enExample)
JP2012504126A5 (enExample)
JP2013521279A5 (enExample)
JP2010535785A5 (enExample)
RU2009141187A (ru) Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с
JP2012504129A5 (enExample)
HRP20150725T1 (hr) Kondenzirani imidazolilimidazoli kao antivirusni spojevi
JP2012504632A5 (enExample)
JP2015512860A5 (enExample)
JP2012512907A5 (enExample)
JP2012504132A5 (enExample)
JP2012144574A5 (enExample)
JP2011520906A5 (enExample)
JP2013509429A5 (enExample)
JP2013508279A5 (enExample)
JP2013532725A5 (enExample)
JP2013507423A5 (enExample)